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Background: Observational research is essential to evaluate the real-life effectiveness of 
asthma treatments and can now make use of outcomes derived from electronic medical records.
Aim: The aim of this study was to investigate the utility of several database outcome measures 
in asthma.
Methods: This study identified cohorts of patients with active asthma from a UK primary care 
database – Optimum Patient Care Research Database – approximately 10% of which was prospec-
tively supplemented with questionnaire data. The “Questionnaire cohort” included patients aged 
18–60 years with valid questionnaire data and 1 year of continuous primary care data. Separate 
“ICS initiation” and “ICS step-up” cohorts included patients aged 5–60 years initiated on inhaled 
corticosteroids (ICSs), who had 1 year of continuous primary care data before, and after, this index 
visit. Database measures of asthma symptom control and exacerbations were identified in the 
Optimum Patient Care Research Database and cross-tabulated with corresponding patient-reported 
(questionnaire) data. Responsiveness of the database outcomes was analyzed, using McNemar’s 
and Wilcoxon’s signed rank tests, and Poisson regression was used to estimate the association 
between database outcomes and future risk of database exacerbations, in the ICS initiation cohort.
Results: The final study included 2,366 Questionnaire cohort patients and 51,404 ICS initia-
tion patients. Agreement between patient-reported and database-recorded exacerbations was 
fair (kappa 0.35). Following the initiation of ICS, database risk domain asthma control (based 
on exacerbations) improved (proportion of patients with uncontrolled asthma decreased from 
24.9% to 18.6%; P<0.001) and mean number of database exacerbations decreased from 0.09 to 
0.08 per patient per year (P=0.001). However, another measure of asthma control which includes 
short-acting beta-agonist prescription as part of the definition did not show this improvement. 
Patients with prior exacerbations had a higher risk of future exacerbation (rate ratio [95% con-
fidence interval], 3.23 [3.03–3.57]).
Conclusion: Asthma control and exacerbations derived from primary care databases were respon-
sive, with the exception of short-acting beta-agonist prescriptions, and useful for risk prediction.
Keywords: electronic health records, real-life effectiveness, asthma control, asthma exacerba-
tions, validation study
Introduction
Randomized controlled trials (RCTs) are used to evaluate the efficacy of drug thera-
pies in controlled conditions and in selected groups of patients. Therapies found to 
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be efficacious in RCTs are not always found to be effective 
in routine care, particularly for chronic conditions such as 
asthma, as a result of real-life factors such as patient hetero-
geneity and suboptimal adherence.1 Classical RCTs also tend 
to include highly selective patient population, representing 
as little as 5% of routine care patients.2 Thus, many clas-
sical RCTs have high internal validity to demonstrate the 
efficacy of treatments in ideal patient populations under 
optimal management, but are more limited in terms of their 
wider generalizability. Observational research to evaluate 
real-life effectiveness therefore offers an important source of 
complementary evidence. Despite increasing acceptance of 
its potential value, concerns about the reliability of observa-
tional research persist3–5 and remain barriers to its widespread 
acceptance and interpretation.
Guidelines recommend that, in clinical practice, the 
assessment of asthma should not only include asthma symp-
tom control, as indicated by variables such as symptoms, 
night waking and reliever use in the previous 1–4 weeks, but 
should also include a risk stratification to assess the patient’s 
risk of exacerbations in the future.6,7 Tools such as Asthma 
Control Test (ACT), Asthma Control Questionnaire (ACQ), 
and the RCP Three Questions have been developed for assess-
ing symptom control in clinical practice, and some (ACT, 
ACQ) are also recommended for use in RCTs.8 There are 
no standardized tools for asthma risk stratification in clinical 
practice or RCTs, but some models have been described.9,10 
One of the strongest predictors of future exacerbations, 
independent of recent symptom control, is the occurrence 
of one or more exacerbations in the previous 12 months.11
Published asthma database studies have been designed 
to utilize outcomes that capture clinical care realities and 
reflect guideline-based definitions.12,13 The appropriate-
ness and utility of these database outcomes, however, have 
not been discussed in the literature to the same extent as 
traditional asthma RCT outcomes.14 Critical appraisal of 
database outcomes is necessary to establish their strengths 
and weaknesses, and consequently the strength of the 
resulting evidence, and to identify opportunities for refine-
ment and improvement. Sustained quality assurance within 
observational research is essential to the establishment of 
meaningful, trusted and standardized outcome measures for 
the field. Furthermore, the development of standardized and 
consensually accepted database outcomes could improve 
research efficiencies and assist health care professionals in 
interpreting the clinical relevance and implications of real-
life research findings.15
To this end, we aimed to evaluate the clinical utility of 
several asthma database outcomes used in our previous 
 studies.16–18 In particular, we investigated the following: 
1) how useful these database outcomes were for providing 
insights into asthma control, compared to information gained 
from patient-reported questionnaires; 2) how well the data-
base outcomes performed in assessing response to effective 
treatment; and 3) how well the database outcomes predicted 
future asthma exacerbations. To do this, we used database 
electronic medical records (EMRs) and linked questionnaire 
data from a large population of patients with asthma managed 
in routine primary care in the UK.
Methods
Data source and permissions
This study used data from the UK’s Optimum Patient Care 
Research Database (OPCRD)19 – a primary care database 
containing anonymized, routinely recorded clinical data from 
over 4.5 million patients. More than 600 primary care prac-
tices across the UK contribute routine EMRs to the OPCRD, 
and ~10% of patients with asthma within the database have 
complementary, linked patient-reported outcomes (PROs) 
captured through self-completed asthma questionnaires that 
were routinely mailed to patients after a clinical visit.
The OPCRD is maintained by Optimum Patient Care 
and has ethical approval from the National Health Service 
(NHS) Research Authority to hold and process unidentifi-
able research data (Research Ethics Committee reference: 
15/EM/0150). This study was approved by the Anonymised 
Data Ethics & Protocol Transparency (ADEPT) Commit-
tee, which is an independent scientific advisory committee 
commissioned by the Respiratory Effectiveness Group for 
the OPCRD (REG; www.effectivenessevaluation.org).20 
This study was designed, implemented and registered in 
accordance with the criteria of the European Network of 
Centres for Pharmacoepidemiology and Pharmacovigilance 
(ENCePP; registration number: EUPAS13194).
study aims
To explore the clinical utility of asthma database outcome 
measures, we evaluated several outcomes from the published 
literature within the OPCRD16–18 and compared them to 
semantically similar PROs, assessed their responsiveness to 
efficacious asthma therapy (inhaled corticosteroids [ICSs]) 
via change in end points before and after treatment initia-
tion and step-up, and evaluated their association with future 
asthma exacerbation risk.
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study design and cohorts
Database outcomes versus PROs
To compare database outcomes and PROs, data from routine 
care EMRs were extracted within a week of patients being 
invited to complete an asthma questionnaire. PROs were 
obtained directly from questionnaires posted to the patients at 
the time their practice data were inputted to the OPCRD (typi-
cally returned within a month of questionnaire mailing), and 
comparator database outcomes were evaluated from routine 
care EMRs over the prior 12 months (a 13-month evaluation 
period in total). The patient cohort with linked EMR/PRO 
data is hereafter referred to as the “Questionnaire cohort”.
Database outcomes: responsiveness and future risk
Separate cohorts were used to investigate the responsiveness 
of asthma database outcomes to efficacious therapy and 
to assess the association between database measures and 
future asthma risk over a 2-year study period. The database 
outcomes were evaluated over one baseline year prior to an 
index date, defined as either 1) the date of a patient’s first ICS 
prescription (“ICS initiation cohort”) or 2) the date at which a 
patient received a ≥50% increase in the maintenance ICS dose 
(“ICS step-up cohort”). The same database outcomes were 
assessed in the year immediately following ICS initiation or 
step-up. Responsiveness was assessed through the evaluation 
of changes in outcome measures from baseline to outcome 
years (pre-/post-therapeutic intervention). Association with 
future risk was evaluated by examining the strength of asso-
ciation between database outcomes (or their disaggregated 
components; described in the “Study outcomes” section) at 
baseline and exacerbations during the outcome year. The 
ICS initiation and step-up cohorts were analyzed separately.
inclusion and exclusion criteria
Patient data for the Questionnaire cohort were extracted over 
the period 2010–2013. Patients were included if they had 
an asthma diagnosis recorded in their EMR, with no subse-
quent “asthma resolved” Read code; had data available for 
extraction up to at least the year 2010 (to allow ≥13 months’ 
complete outcome data at the time the study was conducted); 
were continuously registered in a practice throughout the 
study period; received at least one respiratory prescription 
in the 2 years prior to the index date; had full questionnaire 
data linked to their EMRs; and were aged 18–60 years at the 
time of index date.
Patient data for the ICS initiation and step-up cohorts 
were extracted over the period 1985–2011. Patients were 
included if they were aged 5–60 years at the index date; had a 
Read code “asthma diagnosis ever”; and had at least 2 years’ 
continuous data (at least 1 year before and 1 year after the 
index date). ICS initiation patients were defined by having 
received a minimum of two asthma-related prescriptions in 
the baseline year (none for ICS), an initial ICS prescription 
at the index date and at least two prescriptions for asthma-
related therapies in the outcome year. ICS step-up patients 
had two or more asthma-related prescriptions during the 
baseline year (at least one for ICS), an increase of ≥50% 
baseline ICS dose at their index date ICS prescription and at 
least two asthma-related prescriptions in the outcome year.
Patients were excluded from any of the above cohorts 
if they had a diagnosis for one or more chronic respiratory 
conditions other than asthma, if they received prescriptions 
for multiple ICS types or ICS as part of a fixed-dose combina-
tion therapy at the index date, or if they received maintenance 
oral corticosteroids (OCSs) during the study period (Ques-
tionnaire cohort) or baseline year (ICS cohorts). Datasets 
were examined for duplicate patient entries using unique 
patient IDs. Inclusion and exclusion criteria are illustrated 
in  Figures S1–S3. Lists of Read codes used to select patients 
are included in the Supplementary materials. The rule used to 
identify maintenance OCS is illustrated in Figure S4.
study outcomes
Real-life database outcomes
We examined the properties of three asthma-related data-
base outcomes: a measure of asthma exacerbations and two 
measures of asthma control as described in brief below. Full 
details of outcome definitions can be found in the Supple-
mentary materials.
Database severe exacerbations were defined based on the 
American Thoracic Society/European Respiratory Society 
(ATS/ERS)14 Task Force definition, as the occurrence of 
any of the following during the assessment period: asthma-
related hospital admission or emergency department (ED) 
attendance, or an acute course of OCS with evidence of 
respiratory review.
Two database measures of asthma control, as defined in 
previously published asthma studies,16–18 were evaluated: 1) 
risk domain asthma control (RDAC) and 2) overall asthma 
control (OAC). Patients whose asthma was “uncontrolled” in 
terms of RDAC were those who had any of the following dur-
ing the 12-month assessment period: asthma-related hospital 
admission, ED or outpatient department attendance; acute use 
of OCS with evidence of respiratory review; or antibiotics 
prescribed with evidence of respiratory review. Asthma was 
“controlled” in terms of RDAC for those who had none of 
 
Pr
ag
m
at
ic 
an
d 
O
bs
er
va
tio
na
l R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
7.
19
3.
48
.1
78
 o
n 
14
-F
eb
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Pragmatic and Observational Research 2018:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
32
colice et al
the above events/prescriptions over the assessment period. In 
these studies, patients were classified as “controlled” in terms 
of OAC if they were classified as “controlled” by RDAC and 
(as a proxy for low symptoms) used an average daily dose 
of short-acting beta-agonist (SABA) ≤200 μg (salbutamol) 
or ≤500 μg (terbutaline; Supplementary materials can be 
referred for average daily SABA dose calculation). Patients 
were classified as “uncontrolled” in terms of OAC if they had 
uncontrolled RDAC or used an average daily SABA dose of 
>200 μg salbutamol or >500 μg terbutaline (corresponding 
to >3.65 SABA prescriptions in 12 months).
PRO
The PROs derived from the asthma questionnaires were 
symptom control over the previous 1–4 weeks, modified 
from 2014 Global Initiative for Asthma (GINA) recommen-
dations,7 and patient-reported exacerbations in the previous 
12 months (Figure S5), based on the Asthma Therapy Assess-
ment Questionnaire (ATAQ).21,22
Patient-reported symptom control was determined from 
patient responses to questions about the number of days 
they experienced asthma symptoms during the day, and the 
number of times they had used a reliever inhaler in the last 7 
days. They were also asked whether they had any nighttime 
waking or activity limitation during the past 4 weeks, for 
which the response options were “yes”, “no” or “unsure”. The 
following questionnaire items were then used to categorize 
symptom control: 1) daytime asthma symptoms on more than 
2 days during the previous week, 2) use of a reliever inhaler 
more than two times during the previous week, 3) any night-
time waking due to asthma during the previous 4 weeks, and 
4) any activity limitation due to asthma during the previous 
4 weeks. If none of these items were present, the patient was 
considered to have “well-controlled” symptoms; if one to 
two of these items were present, symptoms were considered 
“partly controlled” and if three to four of these items were 
present, symptoms were considered “uncontrolled”.
The questionnaire also asked about their asthma-related 
health care resource utilization over the previous 12 months. 
Using these data, a patient-reported exacerbation was defined 
as a positive response to any of the following: receipt of a 
course of OCS for worsening asthma, time off work/school 
because of asthma or hospitalization (inpatient admission) 
due to asthma.
statistical analysis
Baseline summary statistics for patient characteristics 
were computed for each of the study cohorts. Counts and 
 percentages were computed for categorical variables, and 
mean values and SDs, or median and interquartile range, for 
continuous variables, depending on distribution.
comparison of PROs and database outcomes 
Database asthma control and exacerbation measures were 
cross-tabulated with corresponding patient-reported mea-
sures. The agreement between database-defined asthma 
control (RDAC and OAC) and patient-reported control 
was assessed using Somers’ d-statistic, which estimates the 
improvement in predicting one variable when using the value 
of a second variable.23 The agreement between database-
defined exacerbations and patient-reported exacerbations was 
assessed using Cohen’s kappa coefficient, which estimates 
the percentage of agreement between two variables that is 
not expected by chance.24
Responsiveness to ics therapy
For each ICS cohort, McNemar tests were used to compare 
the proportion of patients with uncontrolled asthma defined 
by RDAC or OAC, pre- and post-index date. Wilcoxon’s 
signed rank test was used to compare the mean database 
exacerbations in the years before and after the index date.
Prediction of future outcomes
Poisson regression was used to assess the association 
between baseline asthma control, or their disaggregated 
components, and exacerbations during the outcome year. 
Variables were fitted univariably, and unadjusted rate ratios 
(RRs) with 95% confidence intervals (CIs) were estimated. 
For the main analysis, this was carried out separately in the 
ICS initiation and step-up cohorts. A sensitivity analysis 
was carried out in a subgroup of the ICS step-up cohort 
– patients who had stable therapy in the outcome year, 
defined as no add-on therapy and/or a ≥50% increase in 
the existing ICS dose.
All analyses were carried out using IBM SPSS Statistics 
version 21 (IBM Corporation, Armonk, NY, USA), SAS 
version 9.3 (SAS Institute, Cary, NC, USA), and Microsoft 
Office Excel 2013 (Microsoft Corporation, Redmond, WA, 
USA). The level of statistical significance was set at 5%.
Results
Patients
After applying inclusion/exclusion criteria, 2,366 were found 
to be eligible for the Questionnaire cohort, 51,404 for the 
ICS initiation cohort, and 13,131 for the ICS step-up cohort 
(Figures S1–S3).
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Questionnaire cohort
Questionnaire cohort patients had a mean age of 44.4 (SD, 
11.1) years, 40.5% were male, 29.7% had a body mass index 
[BMI] of 30 or above and 24.6% were current smokers 
(Table 1). There was large disparity between the proportion 
of patients with a database-recorded diagnosis of rhinitis 
(8.5%) and the proportion with patient-reported rhinitis 
symptoms (80.8%). During the study period, <1% of patients 
had asthma-related hospital attendance, according to EMRs. 
Two or more prescriptions of acute OCS with evidence of 
respiratory review were identified in 2.2% of patients via 
the database, while two or more instances of OCS use were 
reported by 8.7% of patients.
ics initiation cohort
Patients initiating ICS at the index date had a mean age 
of 29.1 (SD, 17.0) years, 46.5% were male, 21.7% had 
a BMI of 30 or above, and 14.4% were current smokers 
Table 1 Patient characteristics in the Questionnaire cohort
Variables Questionnaire cohort (n=2,366)
age, mean (sD) 44.4 (11.1)
Male, n (%) 959 (40.5)
BMi (kg/m2), n (%)a
<18.5 36 (1.5)
18.5–24.9 793 (34.1)
25–29.9 805 (34.7)
≥30 689 (29.7)
smoking status, n (%)a
nonsmoker 1,478 (62.5)
ex-smoker 303 (12.8)
current smoker 582 (24.6)
Year of index date, n (%)
2010 551 (23.3)
2011 450 (19)
2012 1203 (50.8)
2013 162 (6.8)
Rhinitis, n (%)
Recorded diagnosis 202 (8.5)
Patient reported 1,884 (80.8)
events/prescriptions: observed during study period (12 months before questionnaire completion), n (%)
asthma-related inpatient admissionb (one or more) 5 (0.2)
asthma-related a&e attendanceb (one or more) 4 (0.2)
asthma-related OPD attendanceb (one or more) 3 (0.1)
acute oral corticosteroids with evidence of respiratory reviewc
0 2,135 (90.2)
1 180 (7.6)
2+ 51 (2.2)
antibiotics with evidence of respiratory reviewd
0 1,854 (78.4)
1 356 (15.0)
2+ 156 (6.6)
average saBa daily dosage (μg), mean (sD)e 213.19 (274.7)
events/prescriptions: patient-reported for the previous 12 months, n (%)
Oral corticosteroid use
0 1,915 (80.9)
1 245 (10.4)
2+ 206 (8.7)
number of hospitalizations, mean (sD) 0.08 (0.41)
Notes: aBMi data were missing for 1.82% of patients; smoking status was unknown in 0.1% of patients. basthma-related refers to records coded with a lower respiratory 
code, including asthma and lower respiratory tract infection codes, or a generic hospitalization Read code which has been recorded on the same day as a lower Respiratory 
Consultation (defined in the supplementary materials). cDefined as all courses that are definitely not maintenance therapy; and/or all courses where dosing instructions 
suggest exacerbation treatment (eg, 6, 5, 4, 3, 2, 1 reducing, or 30 mg as directed); and/or all courses with no dosing instructions, but unlikely to be maintenance therapy with 
a code for asthma or a lower respiratory event; and/or no or undefined dosing instructions but definitely not maintenance therapy, where “maintenance therapy” is defined 
as daily dosing instructions of ≤10 mg prednisolone or prescriptions for 1 mg prednisolone tablets. dEvidence of respiratory review is defined in the supplementary materials. 
ecalculation is given in the supplementary materials. The average daily dose of 213 mg salbutamol corresponds to 3.89 saBa prescriptions per year.
Abbreviations: BMi, body mass index; a&e, accident and emergency; OPD, outpatient department; saBa, short-acting beta-agonist.
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(Table 2). During the baseline period, <1% of patients 
had any asthma-related hospital attendance and 0.7% of 
patients had two or more prescriptions of acute OCS with 
evidence of respiratory review. A summary of comorbidities 
is  provided in Table S1.
ics step-up cohort 
Patients stepping up existing ICS therapy at the index date 
had a mean age of 28.9 (SD, 18.0) years, 48.0% were male, 
21.9% had a BMI of 30 or above, and 14.6% were current 
smokers (Table 2). Less than 1% of patients had any asthma-
Table 2 Patient characteristics in the ics initiation and step-up cohorts
Variables ICS initiation (n=51,404) ICS step-up (n=13,131)
Baseline  
period
Outcome  
period
Baseline  
period
Outcome  
period
age, mean (sD) 29.1 (17.0) 28.9 (18.0)
Male, n (%) 23,910 (46.5) 6,301 (48.0)
BMi (kg/m2), n (%)a
<18.5 4,611 (12.0) 1,635 (16.1)
18.5–24.9 14,581 (37.8) 3,605 (35.6)
25–29.9 10,990 (28.5) 2,662 (26.3)
≥30 8342 (21.7) 2,222 (21.9)
smoking status, n (%)a
nonsmoker 30,905 (63.1) 8,360 (66.1)
ex-smoker 11,011 (22.5) 2,433 (19.2)
current smoker 7,027 (14.4) 1,846 (14.6)
Year of index date, median (iQR) 2001 (1996, 2004) 2001 (1997, 2005)
Events/prescriptions: observed during specified period, n (%)
asthma-related inpatient admissionb (one or more) 88 (0.2) 78 (0.2) 40 (0.3) 24 (0.2)
asthma-related a&e attendanceb (one or more) 177 (0.3) 122 (0.2) 86 (0.7) 43 (0.3)
asthma-related OPD attendanceb (one or more) 28 (0.1) 45 (0.1) 16 (0.1) 18 (0.1)
acute oral corticosteroids with evidence of respiratory reviewc
0 47,554 (92.5) 48,122 (93.6) 11,210 (85.4) 11,656 (88.8)
1 3,491 (6.8) 2,670 (5.2) 1,402 (10.7) 1,099 (8.4)
2+ 359 (0.7) 612 (1.2) 519 (4.0) 376 (2.9)
antibiotics with evidence of respiratory reviewd (one or more) 10,956 (21.3) 8,168 (15.9) 3,608 (27.5) 2,810 (21.4)
average saBa daily dosage (μg), n (%)e
0 30,354 (59)
1–100 8,656 (16.8)
101–200 6,578 (12.8)
201+ 5,816 (11.3)
0 10,197 (19.8) 2,847 (21.7)
1–100 8,956 (17.4) 1,561 (11.9)
101–200 13,579 (26.4) 2,880 (21.9)
201–400 10,814 (21.0) 2,799 (21.3)
401+ 7,858 (15.3) 3,044 (23.2)
0 2,714 (20.7)
1–200 3,218 (24.5)
201–400 3,339 (25.4)
401–800 2,428 (18.5)
800+    1,432 (10.9)
Notes: aBMi data were missing in 25.1% of patients in the ics initiation cohort and 22.9% of patients in the ics step-up cohort; smoking status was unknown in 4.8% of 
patients in the ics initiation cohort and 3.7% of patients in the ics step-up cohort. basthma-related refers to records coded with a lower respiratory code, including asthma 
and lower respiratory tract infection codes, or a generic hospitalization Read code which has been recorded on the same day as a Lower Respiratory Consultation (defined 
in the supplementary materials). cDefined as all courses that are definitely not maintenance therapy; and/or all courses where dosing instructions suggest exacerbation 
treatment (eg, 6, 5, 4, 3, 2, 1 reducing, or 30 mg as directed); and/or all courses with no dosing instructions, but unlikely to be maintenance therapy with a code for asthma 
or a lower respiratory event; and/or no or undefined dosing instructions but definitely not maintenance therapy, where “maintenance therapy” is defined as daily dosing 
instructions of ≤10 mg prednisolone or prescriptions for 1 mg prednisolone tablets. dEvidence of respiratory review is defined in the supplementary materials. ecalculation 
is given in the supplementary materials. The average daily saBa use of 200 μg/day corresponds to 3.65 saBa prescriptions per year, and 800 μg/day corresponds to 14.6 
prescriptions per year.
Abbreviations: ics, inhaled corticosteroid; BMi, body mass index; iQR, interquartile range; a&e, accident and emergency; OPD, outpatient department; saBa, short-acting 
beta-agonist.
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related hospital attendance. There was a higher proportion of 
patients with two or more prescriptions of acute OCS with 
evidence of respiratory review in the step-up cohort compared 
to the initiation cohort (4.0% versus 0.7%), and there were 
more prescriptions of SABA in the previous year in the step-
up cohort compared to the initiation cohort. A summary of 
per-cohort comorbidities is provided in Table S1.
Questionnaire cohort: database 
outcomes versus PROs 
asthma control
Two-thirds of patients (67.7%) whose asthma risk was clas-
sified as “controlled” in the baseline year according to the 
database measure RDAC were also classified as having “con-
trolled” (either well or partly) symptoms in the previous 1–4 
weeks, based on patient-reported symptom control (Figure 1). 
Among patients classified as “uncontrolled” over the previ-
ous year in terms of RDAC and OAC, fewer than half were 
also considered “uncontrolled” based on patient-reported 
symptoms in the 1–4 weeks before questionnaire completion 
(47.3% and 47.1%, respectively). The agreement between 
RDAC and patient-reported control was low: Somers’d was 
0.121 (95% CI, 0.083–0.158). The agreement between OAC 
and patient-reported control was slightly higher, but still low: 
Somers’ d was 0.237 (95% CI, 0.196–0.277).
exacerbations
Of the patients who had no database records of exacerba-
tions, 80.6% reported no exacerbations via questionnaire 
(Figure 2). Of those who had one or more database-defined 
exacerbations, 78.9% had one or more self-reported exac-
erbations. Overall, the agreement between patient-reported 
exacerbations and database-defined exacerbations was fair, 
with a Cohen’s kappa of 0.35 (95% CI, 0.31–0.40).
ics cohorts: response to therapy
asthma control
After initiating ICS treatment, the proportion of patients 
with uncontrolled asthma by RDAC decreased from 24.9% 
during baseline to 18.6% during the outcome year (P<0.001; 
Table 3). In the ICS step-up cohort, the proportion of patients 
with uncontrolled asthma by RDAC decreased from 33.4% 
during baseline to 25.7% after the increase in their ICS 
therapy (P<0.001). In contrast, the proportion of patients 
with uncontrolled asthma by OAC paradoxically increased 
from baseline to outcome years for both cohorts, from 33.1% 
Figure 1 comparison of database asthma control (RDac and Oac) and patient-reported symptom control categories.
Note: *Patient-reported symptom control “controlled” category also includes patients whose asthma was “well-controlled” or “partly controlled” based on the 2014 gina 
definition.
Abbreviations: RDac, risk domain asthma control; Oac, overall asthma control; saBa, short-acting beta-agonist; gina, global initiative for asthma.
RDAC =
controlled
GINA “controlled”* GINA “uncontrolled”
RDAC =
uncontrolled
OAC =
controlled
OAC =
uncontrolled
0% 20% 40%
Proportion of patients with GINA symptom control status
60% 80% 100%
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before to 46.7% after ICS initiation (P<0.001) and from 
61.9% to 64.7%, in the ICS step-up cohort (P<0.001). This 
was due to increased SABA prescribing in the post- (versus 
pre-) index year, resulting in an increase in the average cal-
culated daily SABA dose (Table 2).
exacerbations
After initiation of ICS treatment, the mean number of 
database-defined exacerbations decreased from 0.09 (SD, 
0.32) in the baseline year to 0.08 (SD, 0.35) in the outcome 
year (P=0.001; Table 3). After a step-up in the ICS dose, the 
mean number of exacerbations decreased from 0.21 (SD, 
0.60) in the baseline year to 0.16 (SD, 0.52) in the outcome 
year (P<0.001).
Prediction of future outcomes
In univariable Poisson regression models, having uncon-
trolled asthma in terms of RDAC and OAC during the base-
line year was associated with a higher rate of exacerbations 
in the outcome year, for both ICS initiation and ICS step-up 
cohorts (Table 4). In the ICS initiation cohort, the RRs 
with 95% CIs were 3.33 (3.13–3.57) for RDAC and 2.78 
(2.63–3.03) for OAC. In the ICS step-up cohort, the RRs were 
4.35 (4.00–5.00) for RDAC and 3.23 (2.86–3.70) for OAC. 
Most of the disaggregated components of RDAC and OAC at 
baseline also had significant associations with exacerbations 
during the outcome year, except for asthma-related hospital 
admissions (in the ICS initiation cohort) and asthma-related 
outpatient department attendance (both cohorts). An aver-
age daily SABA dose of >200 μg during the baseline year 
(corresponding to dispensing of an average of 3.65 SABA 
inhalers) was associated with RRs of 1.24 (1.11–1.38) and 
1.53 (1.37–1.71) compared to ≤200 μg, in the initiation and 
step-up cohorts, respectively. The strongest association with 
the future exacerbation rate was prescription of acute OCS 
in the baseline year. Compared with patients receiving no 
acute OCS during the baseline year, those prescribed one 
course in the baseline year had over four times the rate of 
Figure 2 comparison of database and patient-reported exacerbations
0 patient-reported
exacerbation
0 database
exacerbation
≥1 database
exacerbations
≥1 patient-reported
exacerbations
0% 20% 40%
Proportion of patients with patient-reported exacerbations
60% 80% 100%
Table 3 Database outcomes before and after the initiation or 
step-up of ics
Type of cohort and 
observed asthma control
Study period P-valuea
Baseline Outcome
ics initiation cohort
RDac status, n (%)
controlled 38,629 (75.1) 41,818 (81.4) <0.001
Uncontrolled 12,775 (24.9) 9,586 (18.6)
Total 51,404 (100) 51,404 (100)
Oac status, n (%)b
controlled 34,367 (66.9) 27,422 (53.3) <0.001
Uncontrolled 17,037 (33.1) 23,982 (46.7)
Total 51,404 (100) 51,404 (100)
number of exacerbations, 
mean (sD)
0.09 (0.32) 0.08 (0.35) 0.001
ics step-up cohort
RDac status, n (%)
controlled 8,750 (66.6) 9,752 (74.3) <0.001
Uncontrolled 4,381 (33.4) 3,379 (25.7)
Total 13,131 (100) 13,131 (100)
Oac status, n (%)b
controlled 4,999 (38.1) 4,637 (35.3) <0.001
Uncontrolled 8,132 (61.9) 8,494 (64.7)
Total 13,131 (100) 13,131 (100)  
number of exacerbations, 
mean (sD)
0.21 (0.60) 0.16 (0.52) <0.001
Notes: aP-values estimated using Mcnemar’s test, for Oac and RDac, and 
Wilcoxon’s signed rank test, for exacerbations. bOac status “controlled” 
corresponds to RDac “controlled” plus saBa prescriptions corresponding to 
an average daily saBa dose of ≤200 μg/day (ie, ≤3.65 saBa prescriptions in 12 
months). 
Abbreviations: ics, inhaled corticosteroids; RDac, risk domain asthma control; 
Oac, overall asthma control.
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exacerbations during the outcome year, and those prescribed 
two or more courses during baseline had over nine times the 
rate of exacerbations during the outcome year.
Results of the sensitivity analysis found consistent results 
within the subgroup of the ICS step-up cohort who had no 
further increases in therapy in the outcome year (Table S2).
Discussion
This study examined real-life database asthma outcomes 
published within the peer-reviewed literature. The findings 
showed that database measures of RDAC and exacerbations 
are responsive to initiation or increases of asthma therapy 
with proven efficacy (ICSs) and may be useful in assessing 
future asthma risk. However, limitations were identified for 
the database measure of OAC because of the inclusion of 
an SABA-based proxy for recent asthma symptoms within 
the definition.
Database outcomes versus PROs
One of the novel features of this study was the comparison 
of patient-reported questionnaire outcomes with database-
reported outcomes for a large number of respondents 
(n=2,366). Despite no previous formal validation, the 
OPCRD questionnaire items were derived from validated 
questionnaires such as the GINA7 assessment of asthma 
symptom control in the past 4 weeks (modified in this study 
to 7 days) and ATAQ21,22 for patient-reported exacerbation 
measures in the past 12 months. In this study, patient-reported 
questionnaire outcomes were compared against database-
recorded control outcomes. While there are published data 
from a previous study designed to validate database-recorded 
asthma measures against questionnaire reports,25 to the best 
of our knowledge, the current study is the first to compare 
database against patient-reported asthma control measures 
in a large observational study design.
Table 4 Association between database components of asthma control and defined exacerbations in the baseline period and 
exacerbations observed in the outcome period
Baseline variable tested Unadjusted rate ratio (95% CI) for  
exacerbations in the outcome period
ICS initiation cohort ICS step-up cohort
RDac=“uncontrolled” 3.33 (3,13–3.57) 4.35 (4.00–5.00)
Oac = “uncontrolled” 2.78 (2.63–3.03) 3.23 (2.86–3.70)
asthma-related inpatient admission 1.75 (0.87–3.53) 2.05 (1.10–3.81)
asthma-related a&e attendance 1.85 (1.18–2.90) 2.21 (1.46–3.34)
asthma-related OPD attendance 6.26 (3.06–12.78) 2.36 (0.77–7.24)
acute course of oral corticosteroidsa
0 1.00 1.00
1 4.43 (4.06–4.84) 4.37 (3.87–4.93)
2+ 9.00 (7.61–10.64) 9.93 (8.62–11.44)
antibiotics prescribed with evidence of respiratory reviewb
0 1.00 1.00
1 2.39 (2.20–2.59) 2.28 (2.00–2.60)
2+ 4.02 (3.62–4.46) 4.79 (4.19–5.48)
any saBa use 1.48 (1.38–1.60) not analyzedc
average saBa daily dosage (μg)d
≤200 1.00 1.00
>200 1.24 (1.11–1.38) 1.53 (1.37–1.71)
average saBa daily dosage (μg)d
0 not analyzedc 0.89 (0.72–1.11)
1–100 1.00
101–200 1.18 (0.96–1.44)
201–400 1.27 (1.04–1.56)
401–800 1.71 (1.38–2.13)
801+ 2.05 (1.63–2.58)
Notes: aDefined as all courses that are definitely not maintenance therapy; and/or all courses where dosing instructions suggest exacerbation treatment (eg, 6, 5, 4, 3, 2, 
1 reducing, or 30 mg as directed); and/or all courses with no dosing instructions, but unlikely to be maintenance therapy with a code for asthma or a lower respiratory 
event; and/or no or undefined dosing instructions but definitely not maintenance therapy, where “maintenance therapy” is defined as daily dosing instructions of ≤10 
mg prednisolone or prescriptions for 1 mg prednisolone tablets. bEvidence of respiratory review is defined in the supplementary materials. ccalculation is given in the 
supplementary materials. dPatient numbers within SABA categories were not sufficient to fit model. An average daily SABA dosage of 200 μg/day corresponds to 3.65 SABA 
prescriptions in 12 months and 800 μg/day corresponds to 14.6 saBa prescriptions in 12 months.
Abbreviations: CI, confidence interval; ICS, inhaled corticosteroid; RDAC, risk domain asthma control; OAC, overall asthma control; A&E, accident and emergency; OPD, 
outpatient department; saBa, short-acting beta-agonist.
 
Pr
ag
m
at
ic 
an
d 
O
bs
er
va
tio
na
l R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
7.
19
3.
48
.1
78
 o
n 
14
-F
eb
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Pragmatic and Observational Research 2018:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
38
colice et al
There was poor agreement between patient-reported 
symptom control and the database-derived control outcomes 
(RDAC and OAC) for the same patients, particularly in the 
identification of patients with uncontrolled symptoms. The 
poor agreement was to be expected, as the database outcomes 
were evaluated over a 12-month period, whereas the PROs 
related to a period of up to 1 month. Furthermore, these 
outcomes were assessing two different domains of asthma 
control: future risk and symptom control, respectively.
In contrast, the database and patient-reported exacerba-
tion measures had equivalent 12-month assessment periods 
and so were more comparable. Patient reports are subjective 
measures and potentially open to both over- and underreport-
ing. Apparent overreporting may have occurred in patients 
who received treatment for more than one exacerbation from 
a single oral steroid prescription, while underreporting may 
have occurred as a result of poor patient recall, especially 
when asked to report events over a 12-month period. Equally, 
under- or over-recording may occur within database mea-
sures as a result of (among other issues) incomplete data. 
The OPCRD, for example, is known to underreport severe 
exacerbations because of the lack of automatic entry within 
primary care records of secondary care events – only those 
that are manually entered by the primary care clinician are 
captured. This is most likely a systematic underreporting 
and, as such, should not affect comparative analyses between 
consecutive time periods (baseline/outcome years), but will 
diminish study power. Overreporting of oral steroid prescrip-
tions may be present in the database if one or more courses 
are prescribed for ad hoc requirements in association with 
an action plan and not actually needed by the patient. For 
all the above reasons, strong agreement was not expected 
between the database outcomes and PROs, although both 
offer differing insights and perspectives: of health care 
resource utilization and the patient experience, respectively. 
Limitations of each data measure must be acknowledged in 
the literature and, where possible, addressed through data 
linkage and triangulation of results.
Utility of database outcomes
RDac
The definition of RDAC examined in these analyses is essen-
tially equivalent to an absence of exacerbations in the patient’s 
recent history and, in this analysis, was assessed over the 
12-month period before and after ICS initiation or step-up. 
It was found to be responsive to ICS use, as the proportion 
of patients with uncontrolled asthma by RDAC decreased 
following treatment initiation and step-up. 
Baseline RDAC, as well as several of its components, 
was found to be associated with future exacerbations in our 
univariable analyses. Exacerbations included in RDAC were 
accident and emergency attendance, acute courses of OCSs, 
and respiratory-related prescription of antibiotics. These find-
ings are consistent with other asthma risk prediction studies, 
which particularly noted the importance of previous ED 
attendance.26,27 The association between RDAC and future 
exacerbations was stronger in the ICS step-up (compared to 
ICS initiation) cohort. This cohort would likely have had a 
greater proportion of patients with more severe asthma, who 
may be subject to disease progression, or of patients who 
were poorly adherent to their treatment.
Oac
The underlying concept of OAC is that it takes into account 
both absence of exacerbations in the previous 12 months (or 
other risk factors for exacerbations) and recent symptom 
control (day-to-day symptoms in the 1–4 weeks prior to 
assessment).7,28 For the present analyses, OAC was based 
on RDAC combined with the capped average daily SABA 
dosage, which in turn was based on the number of SABA 
inhalers prescribed in the previous 12 months. In contrast to 
RDAC alone, OAC performed poorly in terms of responsive-
ness to treatment with the proportion of uncontrolled patients 
increasing following the initiation or step-up of ICS. The 
descriptive tables indicate that the poor performance of this 
measure is likely to be associated with the SABA component 
which, according to prescribing data, increased following 
ICS treatment. This was most notable in the ICS initiation 
cohort and may have been due to inclusion of patients with 
recent-onset asthma, and the appropriate prescribing at the 
ICS initiation visit of an SABA inhaler for symptom relief, 
thus increasing the average population dispensing. However, 
the classification of salbutamol use up to 200 μg/day (ie, 
up to 3.65 inhalers per year) as “controlled” asthma in the 
OAC metric is not consistent with current guidelines, which 
indicate that SABA use >2 days/week (corresponding to 
1.08 inhalers per year) is not consistent with well-controlled 
asthma. The lack of granularity of SABA prescribing data 
limits its utility for the assessment of recent symptom 
control.
This finding, with respect to SABA usage, supports the 
results of a previous cross-sectional study by Davidsen et 
al who reported uncontrolled asthma to be associated with 
increased SABA use, while conversely being associated 
with decreased ICS usage.29 For these reasons, the use of an 
outcome that includes SABA prescribing may be misleading 
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if used in database studies that aim to evaluate the effective-
ness of therapy.
SABA prescribing may still be valuable, however, when 
investigating the risk of future asthma outcomes, as dispens-
ing of three or more SABA inhalers in a year is associated 
with a greater risk of exacerbations,30 and dispensing of ≥12 
SABA inhalers in a year is associated with a greater risk of 
asthma-related deaths.31 In the univariable models, OAC and 
its disaggregated SABA component were both predictive of 
future exacerbations. 
exacerbations
Database-defined exacerbations were found to be a respon-
sive measure: the mean number of exacerbations per year 
decreased from 0.09 to 0.08 following the initiation of ICS 
and decreased from 0.21 to 0.16 following a step-up in the 
ICS dose. However, these data should be interpreted with 
caution, as the mean values were close to 0 (with a wide 
SD) owing to the majority of patients in the ICS initiation 
and step-up cohorts having had no exacerbations in both 
the baseline year (92.2% and 84.8%, respectively) and the 
outcome year (93.4% and 88.5%, respectively).
strengths and limitations
This study used data from a large, well-validated database and 
is representative of patients with asthma in a real-life primary 
care setting. We used outcomes that are readily available in 
real-life primary care databases and have been used in previ-
ous observational research.16–18 We investigated definitions of 
asthma control that represented the two domains of asthma 
control recommended by the ATS/ERS Task Force,14 namely 
current clinical control (now often called symptom control), 
assessed over the previous 1–4 weeks, and future risk (ie, 
individual risk factors for adverse outcomes such as exac-
erbations). Database severe exacerbations were defined in 
line with a definition previously proposed by expert working 
groups.14,32 However, prescribing of antibiotics with evidence 
of respiratory review may not be optimal for identifying 
exacerbations, as there are strong recommendations against 
treatment of asthma exacerbations with antibiotics, and 
changes over time may reflect interventions to reduce use of 
antibiotics rather than changes in asthma control.
The limitations of this study include the inconsistency in 
age ranges across cohorts (perhaps representing the differ-
ent periods of data collection and/or better adherence with 
questionnaire return by older patients), and the time frame of 
the study, as data were extracted over a 25-year period over 
which management approaches have evolved. Lung  function 
assessment was not included in the present assessment of 
asthma control. In the past, lung function was combined 
with symptoms and reliever use in the assessment of asthma 
control, but since the 2014 GINA revision, lung function has 
instead formed part of initial and ongoing risk assessment.33 
The rationale for this change was the known discordance 
between symptom measures and lung function measures, 
and the strong association between low lung function and 
increased risk of exacerbation.33 
We based one of the study cohorts on a step-up of ICS to 
medium dose; however, this does not align with current UK 
guidelines, in which the primary recommendation is step-up 
to low-dose ICS/LABA. As above, the database measure of 
SABA dispensing over a year proved not to be a satisfactory 
proxy for recent asthma symptom control.
Given the present findings, further analyses would be of 
interest, including the responsiveness of PROs and the inves-
tigation of additional independent risk factors for exacerba-
tions such as current smoking that may be included in EMRs.9 
Furthermore, examination of a control group would be help-
ful when investigating responsiveness, to identify changes in 
the proportion of patients with “controlled” asthma or mean 
number of exacerbations in the same time period in a cohort 
in which there were no changes to therapy. Finally, results 
may not be applicable to other countries in which EMR data 
may differ from those in the UK.34
implications for database studies
The findings from this study support the use of database-
derived RDAC and exacerbations to evaluate real-life 
effectiveness of asthma therapies and should increase the 
confidence in observational research that utilizes these 
outcomes. Apart from allowing the analysis of large sample 
sizes, database measures have the benefit of being objec-
tive and routinely recorded and therefore can be evaluated 
in unselected real-world patient groups. Bias may arise, 
however, when relying on the events and prescriptions that 
are identifiable through an electronic database, as aspects of 
actual patient experience may be masked. For example, the 
real-life outcomes in this study may have failed to identify 
multiple exacerbations if the number of OCS tablets dis-
pensed from one prescription was sufficient to treat more than 
one exacerbation, and the number of SABA prescriptions over 
a year performed poorly as a measure of asthma control. The 
validation of database outcomes is important, as the adminis-
trative datasets from which they are derived are not typically 
maintained for research purposes. Furthermore, there is the 
possibility of data entry errors or incomplete data entry, either 
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at random or systematically.35,36 Issues arising from database 
studies should always be transparently reported.
Database outcomes could be most useful in future risk 
studies and to differentiate between risk profiles of different 
asthma phenotypes. The identification of at-risk phenotypes 
requires large studies including heterogeneous patient popu-
lations, which can be infeasible within prospective studies 
and, although lacking RCTs’ traditional requirement for 
strong internal validity, may have high external validity in 
their generalizability to real-world populations.37 Of inter-
est, database studies may also prove useful in assessing the 
effect of health management policies within large popula-
tions of asthma patients treated in routine care settings and 
observed over extended outcome periods. Furthermore, the 
increasing availability of, and access to, large EMR databases 
offers the potential to power interaction studies looking at 
the interplay between different comorbid chronic conditions 
and pharmacotherapies.
Conclusion
Database and patient-reported asthma outcomes offer dif-
ferent, potentially complementary, insights into the “reality” 
of asthma, but they must be thoughtfully selected, clearly 
described and appropriately interpreted when designing, 
conducting and reporting observational research. Database 
asthma measures of RDAC and severe exacerbations are 
responsive descriptions of asthma health status that may be 
useful in the evaluation of real-life asthma treatment effec-
tiveness and future exacerbation risk.
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